| Literature DB >> 34067177 |
Shari S Rogal1,2, Vera Yakovchenko3, Rachel Gonzalez4, Angela Park5, Lauren A Beste6,7, Karine Rozenberg-Ben-Dror8, Jasmohan S Bajaj9,10, Dawn Scott11, Heather McCurdy12, Emily Comstock13, Michael Sidorovic14, Sandra Gibson1, Carolyn Lamorte1, Anna Nobbe15, Maggie Chartier16, David Ross16, Jason A Dominitz17,18, Timothy R Morgan19,20.
Abstract
After implementing a successful hepatitis C elimination program, the Veterans Health Administration's (VHA) Hepatic Innovation Team (HIT) Collaborative pivoted to focus on improving cirrhosis care. This national program developed teams of providers across the country and engaged them in using systems redesign methods and population health approaches to improve care. The HIT Collaborative developed an Advanced Liver Disease (ALD) Dashboard to identify Veterans with cirrhosis who were due for surveillance for hepatocellular carcinoma (HCC) and other liver care, promoted the use of an HCC Clinical Reminder in the electronic health record, and provided training and networking opportunities. This evaluation aimed to describe the VHA's approach to improving cirrhosis care and identify the facility factors and HIT activities associated with HCC surveillance rates, using a quasi-experimental design. Across all VHA facilities, as the HIT focused on cirrhosis between 2018-2019, HCC surveillance rates increased from 46% (IQR 37-53%) to 51% (IQR 42-60%, p < 0.001). The median HCC surveillance rate was 57% in facilities with high ALD Dashboard utilization compared with 45% in facilities with lower utilization (p < 0.001) and 58% in facilities using the HCC Clinical Reminder compared with 47% in facilities not using this tool (p < 0.001) in FY19. Increased use of the ALD Dashboard and adoption of the HCC Clinical Reminder were independently, significantly associated with HCC surveillance rates in multivariate models, controlling for other facility characteristics. In conclusion, the VHA's HIT Collaborative is a national healthcare initiative associated with significant improvement in HCC surveillance rates.Entities:
Keywords: hepatoma; implementation; learning collaborative; screening
Year: 2021 PMID: 34067177 PMCID: PMC8125814 DOI: 10.3390/cancers13092251
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1Mock Screenshot of Advanced Liver Disease Dashboard.
Baseline Facility Characteristics (n = 130) *.
| Characteristics | Facilities |
|---|---|
| Facility complexity | |
| 1 (high) | 77 (59%) |
| 2 | 24 (18%) |
| 3 (low) | 29 (22%) |
| On-site GI specialty care | |
| Yes | 106 (82%) |
| No | 24 (18%) |
| HIT member at facility | |
| Yes | 113 (87%) |
| No | 17 (13%) |
| ALD Dashboard utilization | |
| High | 34 (26%) |
| Low | 96 (74%) |
| HCC Clinical Reminder use | |
| Yes | 20 (15%) |
| No | 110 (85%) |
Abbreviations: GI: gastroenterology, which includes hepatology; HIT: Hepatic Innovation Team; ALD: advanced liver disease; HCC: hepatocellular carcinoma * high ALD Dashboard utilization = above the median number of log-ins.
Figure 2Proportion of Veterans receiving hepatocellular carcinoma surveillance in fiscal year 2018, by facility.
HCC surveillance rates in fiscal years 2018 and 2019 by facility characteristics.
| Facility Characteristics | HCC Surveillance Rate (%) | |||
|---|---|---|---|---|
| FY18 |
| FY19 |
| |
| Complexity | <0.001 | <0.001 | ||
| 1 (high) | 49 | 54 | ||
| 2 | 44 | 47 | ||
| 3 (low) | 36 | 44 | ||
| Quartile of case load | <0.001 | 0.35 | ||
| 1 (low) | 40 | 49 | ||
| 2 | 43 | 50 | ||
| 3 | 49 | 53 | ||
| 4 (high) | 49 | 51 | ||
| On-site GI specialty care | <0.001 | 0.003 | ||
| Yes | 48 | 53 | ||
| No | 37 | 41 | ||
| HIT member at facility | 0.12 | 0.003 | ||
| Yes | 41 | 52 | ||
| No | 46 | 42 | ||
| ALD Dashboard utilization | <0.001 | <0.001 | ||
| High | 51 | 57 | ||
| Low | 40 | 45 | ||
| HCC Clinical Reminder use | <0.001 | <0.001 | ||
| Yes | 53 | 58 | ||
| No | 44 | 47 | ||
Abbreviations: FY=fiscal year; GI: gastroenterology, which includes hepatology; HIT: Hepatic Innovation Team; ALD: advanced liver disease; HCC: hepatocellular carcinoma; high ALD Dashboard utilization = above the median number of log-ins.
Multivariable linear regression models of HCC surveillance rates in fiscal years 2018 and 2019 *.
| Covariates | FY18 | FY19 | ||||
|---|---|---|---|---|---|---|
| β | SE |
| β | SE |
| |
| Complexity | 0.068 | 0.022 | 0.002 | 0.042 | 0.027 | Ns |
| On-site GI specialty care | 0.036 | 0.024 | Ns | 0.066 | 0.030 | 0.026 |
| ALD Dashboard utilization | 0.067 | 0.018 | <0.001 | 0.072 | 0.022 | 0.001 |
| HCC Clinical Reminder | 0.054 | 0.025 | 0.029 | 0.076 | 0.023 | 0.001 |
* Caseload (number of Veterans with cirrhosis) and having a HIT member in the facility were included in the models but were not significantly associated with HCC surveillance in either year. Abbreviation: GI: gastroenterology; HIT: hepatic innovation team; ALD: advanced liver disease; Ns = non-significant (>0.05).